Published in Cancer Res on January 01, 2008
Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst (2008) 3.73
Obesity as a major risk factor for cancer. J Obes (2013) 2.26
A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev (2008) 2.01
The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrinol Metab (2010) 1.67
Fasting C-peptide levels and death resulting from all causes and breast cancer: the health, eating, activity, and lifestyle study. J Clin Oncol (2010) 1.66
Estrogen receptor alpha/beta, AIB1, and TIF2 in colorectal carcinogenesis: do coregulators have prognostic significance? Int J Colorectal Dis (2009) 1.51
Colorectal cancer screening and prevention in women. Dig Dis Sci (2015) 1.46
The role of insulin-like growth factor-I and its binding proteins in glucose homeostasis and type 2 diabetes. Diabetes Metab Res Rev (2009) 1.41
Adipokines linking obesity with colorectal cancer risk in postmenopausal women. Cancer Res (2012) 1.35
Central obesity and atherogenic dyslipidemia in metabolic syndrome are associated with increased risk for colorectal adenoma in a Chinese population. BMC Gastroenterol (2010) 1.26
Postmenopausal levels of endogenous sex hormones and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev (2009) 1.24
Reproductive history and risk of colorectal cancer in postmenopausal women. J Natl Cancer Inst (2011) 1.16
Diabetes mellitus negatively impacts survival of patients with colon cancer, particularly in stage II disease. J Cancer Res Clin Oncol (2010) 1.16
Insulin caused drug resistance to oxaliplatin in colon cancer cell line HT29. J Gastrointest Oncol (2011) 1.15
A prospective study of inflammation markers and endometrial cancer risk in postmenopausal hormone nonusers. Cancer Epidemiol Biomarkers Prev (2011) 1.15
Association between sex hormones and colorectal cancer risk in men and women. Clin Gastroenterol Hepatol (2012) 1.09
Gender, anthropometric factors and risk of colorectal cancer with particular reference to tumour location and TNM stage: a cohort study. Biol Sex Differ (2012) 1.09
Insulin-like growth factor axis and risk of type 2 diabetes in women. Diabetes (2012) 1.08
Testing the proportional hazards assumption in case-cohort analysis. BMC Med Res Methodol (2013) 1.07
Sleep duration and incidence of colorectal cancer in postmenopausal women. Br J Cancer (2013) 1.02
Dietary carbohydrate, glycemic index, and glycemic load in relation to colorectal cancer risk in the Women's Health Initiative. Cancer Causes Control (2008) 1.01
Plasma choline metabolites and colorectal cancer risk in the Women's Health Initiative Observational Study. Cancer Res (2014) 0.98
Sex hormones and colorectal cancer: what have we learned so far? J Natl Cancer Inst (2010) 0.96
Anthropometric correlates of insulin-like growth factor 1 (IGF-1) and IGF binding protein-3 (IGFBP-3) levels by race/ethnicity and gender. Ann Epidemiol (2009) 0.95
Relationship between higher estradiol levels and 9-year mortality in older women: the Invecchiare in Chianti study. J Am Geriatr Soc (2009) 0.95
Association between obesity-related adipokines and colorectal cancer: a case-control study and meta-analysis. World J Gastroenterol (2014) 0.94
Specific metabolic biomarkers as risk and prognostic factors in colorectal cancer. World J Gastroenterol (2014) 0.93
Genetic variants, prediagnostic circulating levels of insulin-like growth factors, insulin, and glucose and the risk of colorectal cancer: the Multiethnic Cohort study. Cancer Epidemiol Biomarkers Prev (2012) 0.92
Hormone therapy, DNA methylation and colon cancer. Carcinogenesis (2010) 0.91
A longitudinal study of serum insulin and glucose levels in relation to colorectal cancer risk among postmenopausal women. Br J Cancer (2011) 0.91
The maternal womb: a novel target for cancer prevention in the era of the obesity pandemic? Eur J Cancer Prev (2011) 0.88
Influence of Obesity and Related Metabolic Alterations on Colorectal Cancer Risk. Curr Nutr Rep (2012) 0.88
Oestrogen and colorectal cancer: mechanisms and controversies. Int J Colorectal Dis (2013) 0.87
Predictors of sustained reduction in energy and fat intake in the Diabetes Prevention Program Outcomes Study intensive lifestyle intervention. J Acad Nutr Diet (2013) 0.87
Insulin, glucose and hepatocellular carcinoma risk in male hepatitis B carriers: results from 17-year follow-up of a population-based cohort. Carcinogenesis (2011) 0.86
Association of estrogen receptor beta variants and serum levels of estradiol with risk of colorectal cancer: a case control study. BMC Cancer (2012) 0.86
Interactions between plasma levels of 25-hydroxyvitamin D, insulin-like growth factor (IGF)-1 and C-peptide with risk of colorectal cancer. PLoS One (2011) 0.86
Estrogen and progesterone-related gene variants and colorectal cancer risk in women. BMC Med Genet (2011) 0.85
The Frequency and Risk Factors of Colorectal Adenoma in Health-Check-up Subjects in South Korea: Relationship to Abdominal Obesity and Age. Gut Liver (2010) 0.84
Serum concentrations of insulin-like growth factor and insulin-like growth factor binding protein 3 and recurrent colorectal adenomas. Cancer Epidemiol Biomarkers Prev (2008) 0.84
Low glycemic load experimental diet more satiating than high glycemic load diet. Nutr Cancer (2012) 0.84
Genetic variation in sex-steroid receptors and synthesizing enzymes and colorectal cancer risk in women. Cancer Causes Control (2010) 0.83
Metabolic syndrome contributes to an increased recurrence risk of non-metastatic colorectal cancer. Oncotarget (2015) 0.81
Vitamin D receptor gene ApaI polymorphism is associated with susceptibility to colorectal cancer. Dig Dis Sci (2009) 0.81
The aromatase gene (CYP19A1) variants and circulating hepatocyte growth factor in postmenopausal women. PLoS One (2012) 0.81
The risk of colonic adenomas and colonic cancer in obesity. Best Pract Res Clin Gastroenterol (2014) 0.80
Association between markers of glucose metabolism and risk of colorectal cancer. BMJ Open (2016) 0.79
Expression of estrogen receptor co-regulators NCoR and PELP1 in epithelial cells and myofibroblasts of colorectal carcinomas: cytoplasmic translocation of NCoR in epithelial cells correlates with better [corrected] prognosis. Virchows Arch (2008) 0.79
A Nested Case-Control Study of Metabolically Defined Body Size Phenotypes and Risk of Colorectal Cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC). PLoS Med (2016) 0.79
Fulvic Acid Attenuates Resistin-Induced Adhesion of HCT-116 Colorectal Cancer Cells to Endothelial Cells. Int J Mol Sci (2015) 0.78
Circulating soluble cytokine receptors and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev (2013) 0.78
Analgesic use and patterns of estrogen metabolism in premenopausal women. Horm Cancer (2014) 0.78
Serum glucose and risk of cancer: a meta-analysis. BMC Cancer (2014) 0.78
Promotion and selection by serum growth factors drive field cancerization, which is anticipated in vivo by type 2 diabetes and obesity. Proc Natl Acad Sci U S A (2013) 0.78
Agreement between circulating IGF-I, IGFBP-1 and IGFBP-3 levels measured by current assays versus unavailable assays previously used in epidemiological studies. Growth Horm IGF Res (2015) 0.77
Chemopreventive efficacy of raloxifene, bexarotene, and their combination on the progression of chemically induced colon adenomas to adenocarcinomas in rats. Cancer Prev Res (Phila) (2013) 0.77
Estrogen Metabolites Are Not Associated with Colorectal Cancer Risk in Postmenopausal Women. Cancer Epidemiol Biomarkers Prev (2015) 0.77
Menopausal hormone therapy and risks of colorectal adenomas and cancers in the French E3N prospective cohort: true associations or bias? Eur J Epidemiol (2012) 0.77
Genetic variation in insulin pathway genes and distal colorectal adenoma risk. Int J Colorectal Dis (2012) 0.76
Raloxifene and antiestrogenic gonadorelin inhibits intestinal tumorigenesis by modulating immune cells and decreasing stem-like cells. Cancer Prev Res (Phila) (2014) 0.76
Circulating IGF-axis protein levels and their relation with levels of plasma adipocytokines and macronutrient consumption in women. Growth Horm IGF Res (2014) 0.76
Evaluating estradiol levels in male patients with colorectal carcinoma. J Clin Diagn Res (2015) 0.75
Association between hyperinsulinemia and increased risk of cancer death in nonobese and obese people: A population-based observational study. Int J Cancer (2017) 0.75
Association between plasma adiponectin levels and colorectal cancer risk in women. Cancer Causes Control (2015) 0.75
Bioavailable insulin-like growth factor-I as mediator of racial disparity in obesity-relevant breast and colorectal cancer risk among postmenopausal women. Menopause (2016) 0.75
A prospective study of soluble receptor for advanced glycation end-products and colorectal cancer risk in postmenopausal women. Cancer Epidemiol (2016) 0.75
Adult BMI Change and Risk of Colon Cancer in Postmenopausal Women. J Obes (2012) 0.75
Diabetes Mellitus and Site-specific Colorectal Cancer Risk in Korea: A Case-control Study. J Prev Med Public Health (2016) 0.75
Type 2 diabetes mellitus and colorectal neoplasia risk in Hispanics: a case-control study. J Diabetes Complications (2015) 0.75
Reproductive and menstrual factors and colorectal cancer incidence in the Women's Health Initiative Observational Study. Br J Cancer (2016) 0.75
Estrogen signaling in colorectal carcinoma microenvironment: expression of ERbeta1, AIB-1, and TIF-2 is upregulated in cancer-associated myofibroblasts and correlates with disease progression. Virchows Arch (2009) 0.75
Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia (1985) 109.13
Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials (1998) 20.39
Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet (1994) 8.34
Haemostatic activation in post-menopausal women taking low-dose hormone therapy: less effect with transdermal administration? Thromb Haemost (2007) 5.91
Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med (2004) 5.65
Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst (1999) 5.27
Reproducibility of plasma hormone levels in postmenopausal women over a 2-3-year period. Cancer Epidemiol Biomarkers Prev (1995) 3.70
Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst (2000) 3.57
Insulin and colon cancer. Cancer Causes Control (1995) 3.48
Increased blood glucose and insulin, body size, and incident colorectal cancer. J Natl Cancer Inst (1999) 2.40
Epidemiology of colorectal cancer revisited: are serum triglycerides and/or plasma glucose associated with risk? Cancer Epidemiol Biomarkers Prev (1994) 2.23
A prospective study of plasma C-peptide and colorectal cancer risk in men. J Natl Cancer Inst (2004) 2.22
A prospective study of C-peptide, insulin-like growth factor-I, insulin-like growth factor binding protein-1, and the risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev (2005) 2.15
A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev (2000) 2.12
Expression of estrogen receptor (ER) subtypes and ERbeta isoforms in colon cancer. Cancer Res (2001) 1.85
Association of markers of insulin and glucose control with subsequent colorectal cancer risk. Cancer Epidemiol Biomarkers Prev (2003) 1.75
Selective loss of estrogen receptor beta in malignant human colon. Cancer Res (2000) 1.63
Estradiol activation of human colon carcinoma-derived Caco-2 cell growth. Cancer Res (1996) 1.54
Hyperinsulinemia, but not other factors associated with insulin resistance, acutely enhances colorectal epithelial proliferation in vivo. Endocrinology (2006) 1.51
Free insulin-like growth factors -- measurements and relationships to growth hormone secretion and glucose homeostasis. Growth Horm IGF Res (2004) 1.50
Serum C-peptide, IGFBP-1 and IGFBP-2 and risk of colon and rectal cancers in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer (2007) 1.49
Plasma C-peptide, insulin-like growth factor-I, insulin-like growth factor binding proteins and risk of colorectal cancer in a nested case-control study: the Japan public health center-based prospective study. Int J Cancer (2007) 1.44
C-peptide measurement: methods and clinical utility. Crit Rev Clin Lab Sci (1984) 1.39
Free insulin-like growth factor I serum levels in 1430 healthy children and adults, and its diagnostic value in patients suspected of growth hormone deficiency. J Clin Endocrinol Metab (1997) 1.33
Insulin, glucose, insulin resistance, and incident colorectal cancer in male smokers. Clin Gastroenterol Hepatol (2006) 1.31
Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women. J Clin Endocrinol Metab (1991) 1.29
Estrogen receptors alpha and beta are inhibitory modifiers of Apc-dependent tumorigenesis in the proximal colon of Min/+ mice. Cancer Res (2007) 1.17
Estrogen receptor beta mRNA in colon cancer cells: growth effects of estrogen and genistein. Biochem Biophys Res Commun (2000) 1.17
Plasma insulin, IGF-binding proteins-1 and -2 and risk of colorectal cancer: a prospective study in northern Sweden. Int J Cancer (2003) 1.13
IGF-1, IGF-2 and IGFBP-3 in prediagnostic serum: association with colorectal cancer in a cohort of Chinese men in Shanghai. Br J Cancer (2001) 1.11
The effects of steroid hormones on a human colon cancer cell line in vitro. Anticancer Res (1992) 1.09
Loss of estrogen inactivation in colonic cancer. J Clin Endocrinol Metab (1999) 1.06
Reciprocal expression of ERalpha and ERbeta is associated with estrogen-mediated modulation of intestinal tumorigenesis. Cancer Res (2001) 1.05
Glycemic status and soluble tumor necrosis factor receptor levels in relation to plasma leptin concentrations among normal weight and overweight US men. Int J Obes Relat Metab Disord (2000) 1.05
ERbeta isoform expression in colorectal carcinoma: an in vivo and in vitro study of clinicopathological and molecular correlates. J Pathol (2005) 1.03
The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women. Menopause (2006) 1.02
Modulation of tumor formation and intestinal cell migration by estrogens in the Apc(Min/+) mouse model of colorectal cancer. Carcinogenesis (2004) 1.01
Differential growth response to oestrogen of premalignant and malignant colonic cell lines. Anticancer Res (1994) 1.01
Overexpression of insulin receptors in fibroblast and ovary cells induces a ligand-mediated transformed phenotype. Mol Endocrinol (1991) 1.00
17beta-Estradiol rapidly stimulates c-fos expression via the MAPK pathway in T84 cells. Mol Cell Endocrinol (2005) 0.98
Differential effects of progestins on the circulating IGF-I system. Maturitas (2003) 0.98
Downregulation of estrogen-metabolizing 17 beta-hydroxysteroid dehydrogenase type 2 expression correlates inversely with Ki67 proliferation marker in colon-cancer development. Int J Cancer (2002) 0.91
Estradiol is trophic for colon cancer in mice: effect on ornithine decarboxylase and c-myc messenger RNA. Gastroenterology (1992) 0.90
Tamoxifen and gonadal steroids inhibit colon cancer growth in association with inhibition of thymidylate synthase, survivin and telomerase expression through estrogen receptor beta mediated system. Cancer Lett (2000) 0.90
Dietary soy isoflavones and estrone protect ovariectomized ERalphaKO and wild-type mice from carcinogen-induced colon cancer. J Nutr (2004) 0.89
Mitogenic effects of oestrogen mediated by a non-genomic receptor in human colon. Br J Surg (2000) 0.84
17Beta-hydroxysteroid dehydrogenase type 2: independent prognostic significance and evidence of estrogen protection in female patients with colon cancer. J Steroid Biochem Mol Biol (2003) 0.84
Elevated insulin receptor protein expression in experimentally induced colonic tumors. Cancer Lett (2004) 0.81
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37
Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation (2010) 30.07
Heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation (2009) 27.89
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA (2004) 23.69
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
Estimating the relative risk in cohort studies and clinical trials of common outcomes. Am J Epidemiol (2003) 18.01
Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation (2008) 15.35
Long-term exposure to air pollution and incidence of cardiovascular events in women. N Engl J Med (2007) 14.90
The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab (2010) 13.29
Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 12.44
Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation (2009) 12.34
Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med (2006) 12.09
Sugar-sweetened beverages, weight gain, and incidence of type 2 diabetes in young and middle-aged women. JAMA (2004) 11.69
Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation (2006) 11.65
Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA (2007) 10.50
Television watching and other sedentary behaviors in relation to risk of obesity and type 2 diabetes mellitus in women. JAMA (2003) 10.05
The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). Arch Intern Med (2008) 9.95
Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care (2008) 9.34
A prospective study of sleep duration and coronary heart disease in women. Arch Intern Med (2003) 9.24
Executive summary: heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation (2010) 9.18
Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA (2005) 9.03
Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med (2006) 8.73
Adiposity as compared with physical activity in predicting mortality among women. N Engl J Med (2004) 8.63
The Women's Health Initiative recruitment methods and results. Ann Epidemiol (2003) 8.42
Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA (2008) 8.32
Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. N Engl J Med (2008) 8.19
Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation (2009) 8.11
Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. Nat Genet (2010) 7.94
A prospective study of self-reported sleep duration and incident diabetes in women. Diabetes Care (2003) 7.40
Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med (2002) 7.32
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet (2009) 7.30
Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology (2010) 7.24
Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA (2010) 7.12
Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care (2006) 7.09
Calcium/vitamin D supplementation and cardiovascular events. Circulation (2007) 6.63
Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation (2003) 6.62
Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 6.51
Body-mass index and mortality among adults with incident type 2 diabetes. N Engl J Med (2014) 6.51
Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37 485 individuals. Arch Intern Med (2010) 6.48
Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res (2008) 6.47
C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39
Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N Engl J Med (2009) 6.16
Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study. Circulation (2004) 6.15
Autonomic nerve development contributes to prostate cancer progression. Science (2013) 6.11
Protection against persistence of hepatitis C. Lancet (2002) 5.94
Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med (2004) 5.86
Dietary sugars intake and cardiovascular health: a scientific statement from the American Heart Association. Circulation (2009) 5.82
Low-fat dietary pattern and weight change over 7 years: the Women's Health Initiative Dietary Modification Trial. JAMA (2006) 5.75
Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obes Res (2004) 5.74
Coffee consumption and risk for type 2 diabetes mellitus. Ann Intern Med (2004) 5.67
Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst (2005) 5.52
Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst (2005) 5.29
Multivitamins in the prevention of cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA (2012) 5.25
Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet (2009) 5.22
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet (2011) 5.21
Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet (2009) 5.14
Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA (2008) 5.13
Systematic review: Vitamin D and calcium supplementation in prevention of cardiovascular events. Ann Intern Med (2010) 5.05
Physical activity, including walking, and cognitive function in older women. JAMA (2004) 4.90
A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet (2010) 4.89
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet (2012) 4.87
Effects of estrogen plus progestin on health-related quality of life. N Engl J Med (2003) 4.83
Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med (2009) 4.80
The carcinogenicity of human papillomavirus types reflects viral evolution. Virology (2005) 4.72
Red meat consumption and mortality: results from 2 prospective cohort studies. Arch Intern Med (2012) 4.72
Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes (2004) 4.67
Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet (2012) 4.63
Design and implementation of the Hispanic Community Health Study/Study of Latinos. Ann Epidemiol (2010) 4.61
Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol (2005) 4.55
Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA (2008) 4.42